211 related articles for article (PubMed ID: 16251293)
1. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents.
Walsh TJ; Adamson PC; Seibel NL; Flynn PM; Neely MN; Schwartz C; Shad A; Kaplan SL; Roden MM; Stone JA; Miller A; Bradshaw SK; Li SX; Sable CA; Kartsonis NA
Antimicrob Agents Chemother; 2005 Nov; 49(11):4536-45. PubMed ID: 16251293
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients.
Li CC; Sun P; Dong Y; Bi S; Desai R; Dockendorf MF; Kartsonis NA; Ngai AL; Bradshaw S; Stone JA
Antimicrob Agents Chemother; 2011 May; 55(5):2098-105. PubMed ID: 21300834
[TBL] [Abstract][Full Text] [Related]
3. Potential for interactions between caspofungin and nelfinavir or rifampin.
Stone JA; Migoya EM; Hickey L; Winchell GA; Deutsch PJ; Ghosh K; Freeman A; Bi S; Desai R; Dilzer SC; Lasseter KC; Kraft WK; Greenberg H; Waldman SA
Antimicrob Agents Chemother; 2004 Nov; 48(11):4306-14. PubMed ID: 15504857
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of caspofungin in older infants and toddlers.
Neely M; Jafri HS; Seibel N; Knapp K; Adamson PC; Bradshaw SK; Strohmaier KM; Sun P; Bi S; Dockendorf MF; Stone JA; Kartsonis NA
Antimicrob Agents Chemother; 2009 Apr; 53(4):1450-6. PubMed ID: 19114680
[TBL] [Abstract][Full Text] [Related]
5. Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations.
Mistry GC; Migoya E; Deutsch PJ; Winchell G; Hesney M; Li S; Bi S; Dilzer S; Lasseter KC; Stone JA
J Clin Pharmacol; 2007 Aug; 47(8):951-61. PubMed ID: 17660480
[TBL] [Abstract][Full Text] [Related]
6. Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants.
Migoya EM; Mistry GC; Stone JA; Comisar W; Sun P; Norcross A; Bi S; Winchell GA; Ghosh K; Uemera N; Deutsch PJ; Wagner JA
J Clin Pharmacol; 2011 Feb; 51(2):202-11. PubMed ID: 20679501
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age.
Sáez-Llorens X; Macias M; Maiya P; Pineros J; Jafri HS; Chatterjee A; Ruiz G; Raghavan J; Bradshaw SK; Kartsonis NA; Sun P; Strohmaier KM; Fallon M; Bi S; Stone JA; Chow JW
Antimicrob Agents Chemother; 2009 Mar; 53(3):869-75. PubMed ID: 19075070
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, efficacy, and safety of caspofungin in Japanese pediatric patients with invasive candidiasis and invasive aspergillosis.
Mori M; Imaizumi M; Ishiwada N; Kaneko T; Goto H; Kato K; Hara J; Kosaka Y; Koike K; Kawamoto H; Maeda N; Yoshinari T; Kishino H; Takahashi K; Kawahara S; Kartsonis NA; Komada Y
J Infect Chemother; 2015 Jun; 21(6):421-6. PubMed ID: 25701307
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.
Maertens JA; Madero L; Reilly AF; Lehrnbecher T; Groll AH; Jafri HS; Green M; Nania JJ; Bourque MR; Wise BA; Strohmaier KM; Taylor AF; Kartsonis NA; Chow JW; Arndt CA; DePauw BE; Walsh TJ;
Pediatr Infect Dis J; 2010 May; 29(5):415-20. PubMed ID: 20431381
[TBL] [Abstract][Full Text] [Related]
10. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.
Zaoutis TE; Jafri HS; Huang LM; Locatelli F; Barzilai A; Ebell W; Steinbach WJ; Bradley J; Lieberman JM; Hsiao CC; Seibel N; Laws HJ; Gamba M; Petrecz M; Taylor AF; Strohmaier KM; Chow JW; Kartsonis NA; Ngai AL
Pediatrics; 2009 Mar; 123(3):877-84. PubMed ID: 19255017
[TBL] [Abstract][Full Text] [Related]
11. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.
Stone JA; Holland SD; Wickersham PJ; Sterrett A; Schwartz M; Bonfiglio C; Hesney M; Winchell GA; Deutsch PJ; Greenberg H; Hunt TL; Waldman SA
Antimicrob Agents Chemother; 2002 Mar; 46(3):739-45. PubMed ID: 11850256
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin.
Maschmeyer G; Glasmacher A
Mycoses; 2005 Jul; 48(4):227-34. PubMed ID: 15982202
[TBL] [Abstract][Full Text] [Related]
13. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis.
Betts RF; Nucci M; Talwar D; Gareca M; Queiroz-Telles F; Bedimo RJ; Herbrecht R; Ruiz-Palacios G; Young JA; Baddley JW; Strohmaier KM; Tucker KA; Taylor AF; Kartsonis NA;
Clin Infect Dis; 2009 Jun; 48(12):1676-84. PubMed ID: 19419331
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.
Louie A; Deziel M; Liu W; Drusano MF; Gumbo T; Drusano GL
Antimicrob Agents Chemother; 2005 Dec; 49(12):5058-68. PubMed ID: 16304173
[TBL] [Abstract][Full Text] [Related]
15. Lack of pharmacokinetic drug interaction between oral posaconazole and caspofungin or micafungin.
Krishna G; Vickery D; Ma L; Yu X; Noren C; Power E; Beresford E; Medlock M
J Clin Pharmacol; 2011 Jan; 51(1):84-92. PubMed ID: 20489029
[TBL] [Abstract][Full Text] [Related]
16. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
[TBL] [Abstract][Full Text] [Related]
17. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.
Sivak O; Bartlett K; Risovic V; Choo E; Marra F; Batty DS; Wasan KM
J Pharm Sci; 2004 Jun; 93(6):1382-9. PubMed ID: 15124198
[TBL] [Abstract][Full Text] [Related]
18. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
[TBL] [Abstract][Full Text] [Related]
19. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections.
Benjamin DK; Driscoll T; Seibel NL; Gonzalez CE; Roden MM; Kilaru R; Clark K; Dowell JA; Schranz J; Walsh TJ
Antimicrob Agents Chemother; 2006 Feb; 50(2):632-8. PubMed ID: 16436720
[TBL] [Abstract][Full Text] [Related]
20. Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study.
Kartsonis NA; Saah A; Lipka CJ; Taylor A; Sable CA
J Antimicrob Chemother; 2004 May; 53(5):878-81. PubMed ID: 15044431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
